Cut-Price Generics Set To Challenge Boehringer’s Nintedanib In India

 
• By Anju Ghangurde

Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.

Lungs
India Competition Arrives For Boehringer's Nintedanib • Source: Shutterstock

More from India

More from Focus On Asia